HPV: újonnan felismert kockázati tényező a fej-nyaki rákok kialakulásában cgelectric.
Ability and willingness to participate in the study. Subject agrees papilloma a vírus gi refrain from using prescription or supplemental antiviral medications without obtaining permission of the Treating Papilloma a vírus gi. Voluntary written informed consent.
Exclusion Criteria: 1. Subject has been vaccinated against HPV 2.
Interval between a delivery and T0 is less than 3 months 3. Subject has a gynecologic surgical intervention between T0 and T1 4. Subject is diagnosed HPV negative at T0 5.
Subject has a adeno carcinoma in situ. Females with child bearing potential who are not using a reliable, medically accepted method of birth control 7. Pregnant or breast-feeding female, or women planning to become pregnant during the trial.
Medical history of immunosuppression by radiotherapy, chemotherapy, immuno-modulatory drugs, or HIV. Medical history of any severe diseases like hepatitis, renal or liver dysfunction, car-diovascular, gastrointestinal, malignant tumor sor psychiatric disorders etc. Intake or application of antivirals or other prohibited concomitant medication within 30 days prior to application of AV2, or patients who plan to take such drugs during the trial.
Optimizing GI Testing: Molecular Diagnostic Testing for Common Stool Pathogens
Known or suspected allergic or adverse response to the investigational product AV2-DM Antiviral spray, it's components, olive oil or d-limonene. Inability to follow the study protocol.